Poets | Bookstore | Poem of the Day | Top 40 | Search | Comments | Privacy
September 15th, 2014 - we have 234 poets, 8,025 poems and 278,943 comments.
Analysis and comments on Maple by Robert Frost

[1] 2

Comment 11 of 11, added on April 11th, 2014 at 3:08 PM.
It depends on the tr

It depends on the trteemant you have. There is a book just out called You
Can Beat Prostate Cancer written by Robert J. Marckini a prostate cancer
survivor. The book tells alot about prostate cancer and then outlines all
of the trteemants available today plus the Pros and cons of each including
side effects.. It is a great book and any one with prostate cancer or
prostate problems should have it.. It can be purchased at Barnes and Noble
and on ebay I think plus some other places.I had Prostate Cancer in 2005
and was treated with Proton Radiation at Loma Linda Universtiy Medical
Center in Loma Linda California.. Proton Radiation usually has no side
effects and has about a 90% cure rate..I personally believe it is the very
best trteemant available today.. It is very different from conventional
radiation in that about 85-90% of the trteemant energy is released exactly
at the point being treated. Therefore, surrounding tissues and organs are
not damaged by the radiation as in conventional radiation.. therefore one
has little to no side effects. Proton Radiation basically treats only the
area needing to be treated. There is a website called Proton Bob(Bob
stands for brotherhood of the ballon) The website is great ..if you or any
a friend or relative have Prostate cancer .. please read the website.. and
especially read the Patient Testimonial section.. Every one who has ever
had Prostate Cancer and was treated with Proton Radiation is completely
sold on it.. and why not.. it has no side effects and as good if not better
cure rate than all the other trteemants..Many doctors have been reluctant
to recommend Proton Radition, they didnt know about it, considered it
experimental or it was a money thing.. you dont make any money sending your
patients somewhere else for trteemants.. However some have started to take
notice and can no longer ignore the amazing results that Loma Linda
Univerty Medical Center has had with it over the last 17 years.. It is now
being offered at several other hospitals and several trteemant facilities
are currenty under construction.. It is offered at M D Anderson in Houston(
just opened last may), Mass General in Boston(Harvard) a hospital in
Jacksonville florida and one in Indiana I think.. the Proton Bob website
gives all the locations There are some really bad side effects with most
of the other trteemants. With Proton Radiation, it does not effect your
sexual ability as most of the other trteemants do. I was not sick one day
during the trteemants or any time after my trteemants.. it was like a
vacation almost.. Only side effect I had was driving on interstate 10 out
in California now that was bad!!!!Ohh my PSA is now .13 and dropping
thats point one three!!!!If you have any questions any experience with
Prostate Cancer or Proton Radiation, feel free to email me, I will also be
glad to visit with you on the phone about it if you or a relative or friend
has Prostate Cancer.. Having Prostate cancer was not that big of thing
with me especially after having Proton Radiation.. It is a good and simple
cure..

Chaimaa from Czech Republic
Comment 10 of 11, added on September 16th, 2013 at 11:01 AM.
enexyra

o nikos pinei iremos to kafedaki tou kapou sto syntagma,
kapoia stigmi vlepei to filo t to giwrgo kai pernaei apo
mprosta tou kai ton fonazei.
-giwrgo ela na se kerasw kafedaki kai na ta poume

-ti einai ola auta ta xartia pou exeis mprosta sou?

-logariasmoi giorgo mou eutixws tous eksoflisa kai to
apolamvanw....

-ti? kerdises to laxeio?

-oxi niko mou alla ekana kati pou mporousa na to kanw
eixe i gynaika mou kapoia kosmimata poume den ta forouse
kai kati skeuh asimenia pou den ta xrisimopoiousame,
ta peira loipon kai phga edw stin koloktroni 9 ston kurio
spiropoulo kai ta poulisa.
mou edwse kala leuta kai etsi eksoflisa olous tous logariasmous
mou kai tora to apolamvanw....

LogPanagiotis from Estonia
Comment 9 of 11, added on May 25th, 2013 at 12:04 PM.
Gains for a 4th Week in a Row, and Milestones, Too ujm

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223
dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found
below the bladder and in front of the rectum. The male sex hormone
testosterone stimulates the prostate tumors to grow. According to the
National Cancer Institute, an estimated 238,590 men will be diagnosed with
prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product¡¯s
prescription drug user fee goal date of Aug. 14, 2013, the date the agency
was scheduled to complete review of the drug application. The FDA reviewed
Xofigo under the agency¡¯s priority review program, which provides for an
expedited review of drugs that appear to provide safe and effective therapy
when no satisfactory alternative therapy exists, or offer significant
improvement compared to marketed products.

¡°Xofigo binds with minerals in the bone to deliver radiation directly to
bone tumors, limiting the damage to the surrounding normal tissues,¡± said
Richard Pazdur, M.D., director of the Office of Hematology and Oncology
Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is
the second prostate cancer drug approved by the FDA in the past year that
demonstrates an ability to extend the survival of men with metastatic
prostate cancer.¡±

In August 2012, the FDA approved Xtandi to treat men with metastatic
castration-resistant prostate cancer that has spread or recurred, even with
medical or surgical therapy to minimize testosterone. Xtandi is approved
for patients who have previously been treated the chemotherapy drug
docetaxel.

Xofigo¡¯s safety and effectiveness were evaluated in a single clinical
trial of 809 men with symptomatic castration-resistant prostate cancer that
spread to bones but not to other organs. Patients were randomly assigned to
receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a
pre-planned interim analysis showed men receiving Xofigo lived a median of
14 months compared to a median of 11.2 months for men receiving placebo. An
exploratory updated analysis conducted later in the trial confirmed
Xofigo¡¯s ability to extend overall survival.

The most common side effects reported during clinical trials in men
receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg,
ankle or foot. The most common abnormalities detected during blood testing
included low levels of red blood cells (anemia), lymphocytes
(lymphocytopenia), white blood cells (leukopenia), platelets
(thrombocytopenia) and infection-fighting white blood cells (neutropenia).

12312
12312

gandigoBligma from Ghana
Comment 8 of 11, added on May 25th, 2013 at 9:46 AM.
Farming on Mars? NASA ponders food supply ugn

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223
dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found
below the bladder and in front of the rectum. The male sex hormone
testosterone stimulates the prostate tumors to grow. According to the
National Cancer Institute, an estimated 238,590 men will be diagnosed with
prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product¡¯s
prescription drug user fee goal date of Aug. 14, 2013, the date the agency
was scheduled to complete review of the drug application. The FDA reviewed
Xofigo under the agency¡¯s priority review program, which provides for an
expedited review of drugs that appear to provide safe and effective therapy
when no satisfactory alternative therapy exists, or offer significant
improvement compared to marketed products.

¡°Xofigo binds with minerals in the bone to deliver radiation directly to
bone tumors, limiting the damage to the surrounding normal tissues,¡± said
Richard Pazdur, M.D., director of the Office of Hematology and Oncology
Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is
the second prostate cancer drug approved by the FDA in the past year that
demonstrates an ability to extend the survival of men with metastatic
prostate cancer.¡±

In August 2012, the FDA approved Xtandi to treat men with metastatic
castration-resistant prostate cancer that has spread or recurred, even with
medical or surgical therapy to minimize testosterone. Xtandi is approved
for patients who have previously been treated the chemotherapy drug
docetaxel.

Xofigo¡¯s safety and effectiveness were evaluated in a single clinical
trial of 809 men with symptomatic castration-resistant prostate cancer that
spread to bones but not to other organs. Patients were randomly assigned to
receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a
pre-planned interim analysis showed men receiving Xofigo lived a median of
14 months compared to a median of 11.2 months for men receiving placebo. An
exploratory updated analysis conducted later in the trial confirmed
Xofigo¡¯s ability to extend overall survival.

The most common side effects reported during clinical trials in men
receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg,
ankle or foot. The most common abnormalities detected during blood testing
included low levels of red blood cells (anemia), lymphocytes
(lymphocytopenia), white blood cells (leukopenia), platelets
(thrombocytopenia) and infection-fighting white blood cells (neutropenia).

12312
12312

gandigoBligma from Greece
Comment 7 of 11, added on May 25th, 2013 at 9:44 AM.
Pregnant Beyonc¨¦: See Fashion Photos From When She Was Expecting Blue Ivy wbd

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223
dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found
below the bladder and in front of the rectum. The male sex hormone
testosterone stimulates the prostate tumors to grow. According to the
National Cancer Institute, an estimated 238,590 men will be diagnosed with
prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product¡¯s
prescription drug user fee goal date of Aug. 14, 2013, the date the agency
was scheduled to complete review of the drug application. The FDA reviewed
Xofigo under the agency¡¯s priority review program, which provides for an
expedited review of drugs that appear to provide safe and effective therapy
when no satisfactory alternative therapy exists, or offer significant
improvement compared to marketed products.

¡°Xofigo binds with minerals in the bone to deliver radiation directly to
bone tumors, limiting the damage to the surrounding normal tissues,¡± said
Richard Pazdur, M.D., director of the Office of Hematology and Oncology
Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is
the second prostate cancer drug approved by the FDA in the past year that
demonstrates an ability to extend the survival of men with metastatic
prostate cancer.¡±

In August 2012, the FDA approved Xtandi to treat men with metastatic
castration-resistant prostate cancer that has spread or recurred, even with
medical or surgical therapy to minimize testosterone. Xtandi is approved
for patients who have previously been treated the chemotherapy drug
docetaxel.

Xofigo¡¯s safety and effectiveness were evaluated in a single clinical
trial of 809 men with symptomatic castration-resistant prostate cancer that
spread to bones but not to other organs. Patients were randomly assigned to
receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a
pre-planned interim analysis showed men receiving Xofigo lived a median of
14 months compared to a median of 11.2 months for men receiving placebo. An
exploratory updated analysis conducted later in the trial confirmed
Xofigo¡¯s ability to extend overall survival.

The most common side effects reported during clinical trials in men
receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg,
ankle or foot. The most common abnormalities detected during blood testing
included low levels of red blood cells (anemia), lymphocytes
(lymphocytopenia), white blood cells (leukopenia), platelets
(thrombocytopenia) and infection-fighting white blood cells (neutropenia).

12312
12312

gandigoBligma from Algeria
Comment 6 of 11, added on December 5th, 2011 at 10:24 AM.

i dont understand.

Tim
Comment 5 of 11, added on December 5th, 2011 at 10:18 AM.

i dont understand.

Tim
Comment 4 of 11, added on July 28th, 2011 at 7:11 AM.
sZeghadEsgbRLZ

A bit surprised it seems to simple and yet uesful.

Magdelina from Zambia
Comment 3 of 11, added on January 28th, 2010 at 12:00 AM.
hotel in der tuerkei

Foreign Clear,trip use press yesterday theatre press lunch fair thanks
upper recently loss everything trend treaty finally school beyond arise top
holiday examination cover mention carefully error opportunity opposition
extend capacity project lose right task realize review fire also procedure
peace annual play repeat mouth select employ choose threat head quite
merely date left in species well working management surprise score role
battle stand shoulder right farmer understanding colour sing next
population line choice from ball plate competition representative reference
derive activity reveal bone fly lip message island

hotel in der tuerkei
Comment 2 of 11, added on March 22nd, 2006 at 11:09 AM.

i hate this poem i never did and never will so im not ever gona look at it
again

max from United States

This poem has been commented on more than 10 times. Click below to see the other comments.
[1] 2
Share |


Information about Maple

Poet: Robert Frost
Poem: 5. Maple
Volume: New Hampshire
Year: 1923
Added: Feb 20 2003
Viewed: 20572 times


Add Comment

Do you have any comments, criticism, paraphrasis or analysis of this poem that you feel would assist other visitors in understanding this poem better? If they are accepted, they will be added to this page of American Poems. Together we can build a wealth of information, but it will take some discipline and determination.

Do not post questions, pleas for homework help or anything of the sort, as these types of comments will be removed. The proper place for questions is the poetry forum.

Please note that after you post a comment, it can take up to an hour before it is visible on the website! Rest assured that your comment is not lost, so don't enter your comment again.

Comment on: 5. Maple
By: Robert Frost

Name: (required)
E-mail Address: (required)
Country:
Show E-mail Address:
Yes No
Subject:
Poem Comments:

Poem Info

Frost Info
Copyright © 2000-2012 Gunnar Bengtsson. All Rights Reserved. Links | Bookstore